The Effect of Omalizumab (Xolair) on Improving Neuropsychiatric Symptoms in a Subset of ASD Patients With Atopic Disease and Elevated Total IgE Levels

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Omalizumab (Primary)
Indications Allergic rhinitis; Asthma; Atopic dermatitis; Pervasive child development disorders
Focus Therapeutic Use

11 Aug 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
16 Oct 2020 Planned number of patients changed from 20 to 18.
16 Oct 2020 Planned End Date changed from 1 Oct 2021 to 1 Jan 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com